The G-BA starts the development of a new DMP for obesity

This new DMP for obesity should consider and combine various therapeutic approaches to offer the best possible care, treat patients with obesity
German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
This new DMP for obesity should consider and combine various therapeutic approaches to offer the best possible care, treat patients with obesity
Early benefit assessments are completed within 12 months, while method assessments used to take around 3 years. In 2020, the G-BA introduced
Since 2011, 7 new laws were added to AMNOG to dictate the early benefit assessment of drugs. Therefore, it is often called
The G-BA has now completed its benefit assessment of the CAR-T therapy, Tecartus, which is indicated for the treatment of mantle cell
The AMNOG law dictates that every pharmaceutical product with a new chemical entity which received its marketing authorization on or after 1